Search for Stocks /

Advanced Enzyme:₹172 Cr Revenue. Margins Got Squashed. But 9M+15% Says Everything’s Fine

Advanced Enzyme Technologies Q3 FY26 | EduInvesting
Q3 FY26 Results · Quarterly Reporting (Jan–Mar FY)

Advanced Enzyme:
₹172 Cr Revenue. Margins Got Squashed.
But 9M+15% Says Everything’s Fine

A company making enzymes that break down proteins is currently breaking down its own margins. Q3 was “soft,” the CFO said. Which in auditor-speak means “we got absolutely demolished.” But don’t worry—the turnaround is coming in Q1 next year. Pinky promise.

Market Cap₹3,038 Cr
CMP₹272
P/E Ratio21.1x
Div Yield1.92%
ROCE13.1%

The Enzyme That’s Slowly Digesting Investor Hopes

  • 52-Week High / Low₹367 / ₹259
  • Q3 FY26 Revenue₹172 Cr
  • Q3 PAT₹43.2 Cr
  • Q3 EPS₹3.80
  • Annualised EPS (Q3×4)₹15.20
  • Book Value₹133
  • Price to Book2.05x
  • Dividend Yield1.92%
  • Debt / Equity0.02x
  • 9M FY26 Revenue₹543 Cr
CEO’s Honest Confession (Buried in Footnote): Q3 was operationally soft. The margin chart looks like a ski slope. U.S. nutraceutical demand is “uncertain.” But hey, 9M revenue is up 15% YoY, so technically we’re still winning. Just not in quarters three. Or maybe four. We’ll get back to you on that.

India’s Enzyme King Is Having an Identity Crisis

Advanced Enzyme Technologies. The name alone screams “I make things that make things work.” Which they do. They make enzymes. Enzymes are proteins that catalyze chemical reactions. They help pharma companies, nutraceutical companies, animal feed manufacturers, textile mills, and breweries do their jobs. Think of enzymes as the microscopic workers inside your supplement bottle. Invisible, essential, and deeply unglamorous.

The company is the 1st Indian enzyme manufacturer and 2nd integrated enzyme company globally. They export to 45+ countries. They have 700+ customers. They own 9 manufacturing plants and operate 7 R&D centres. On paper, this is a fortress. On the stock price chart, it’s a ski slope.

Here’s the thing: Enzyme companies are specialist manufacturers in a niche market. They’re not sexy. You won’t see them on Shark Tank. Your mom won’t ask you at dinner, “Beta, did you invest in enzymes?” But they’re profitable, they generate cash, and they’re growing. Just… slowly. And with more turbulence than a turbocharged flight to Goa.

FY25 revenue was ₹637 crore. FY26 target? Nobody knows. But Q3 happened, margins got destroyed, and now management is talking about a “roller coaster” ride through 2026. Buckle up.

Concall Gold Nugget (Feb 2026): Management said growth “13% to 15%… continuous basis” over 3–5 years, but also said “the ride will be roller coaster.” This is the corporate equivalent of “I promise to call you back” — technically not a lie, just deeply optimistic.

They Ferment. You Consume. Universe Continues.

Read Full 16 Point breakdown. Continue reading →
Members get full access to every article.
Become a member
Already a member? Log in
Read Full 16 Point breakdown. Continue reading →